TABLE 1.
Demographic information of participants in the psilocybin arm of the trial.
| Overall | |
|---|---|
| Total patient number included in model | 29 |
| Total patient number excluded from model | 1 |
| Demographics of those included | |
| Age, years—mean, SD (range) | 42.8, 11.6 (21–64) |
| Females, number (%) | 11 (38) |
| Caucasian Ethnicity, number (%) a | 27 (93) |
| Employment status—number (%) | |
| Employed | 20 (69) |
| Unemployed | 7 (24) |
| Student | 2 (7) |
| University-level education, number (%) | 22 (76) |
| Past psilocybin use, number (%) | 7 (24) |
| Weekly alcohol (United Kingdom units)—mean, SD (range) | 4.8, 5.4 (0–20) |
| Clinical | — |
| Illness duration, years—mean, SD (range) | 22.2, 10.9 (3–44) |
| HAMD-17 scores at pre-treatment baseline-mean, SD (range) b | 19.2, 2.3 (16–23) |
| QIDS-16 scores at pre-treatment baseline—mean, SD (range) c | 14.7, 3.9 (7–23) |
| No. past psychiatric medications—mean, SD (range) | 2.2, 1.7 (0–6) |
| Discontinued psychiatric medication for trial, number (%) | 11 (38) |
| Past psychotherapy, number (%) | 27 (93) |
Pre-treatment baseline was 7–10 days before dosing-day 1.
a
Race was reported by the patients.
b
The scores on the 17-item Hamilton Depression Rating Scale (HAM-D-17) range from 0 to 50, with higher scores indicating Greater depression. At screening, which was typically a few weeks before pre-treatment baseline, all the patients. Had a score of at least 17 on the HAM-D-17. The depression scores reported in this table are from pre-treatment baseline. And not screening.
c
The scores on the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR-16) range from 0 to 27, with higher scores indicating greater depression.